Review ArticleReviews and Commentaries

Rhabdomyolysis: Pathogenesis, Diagnosis, and Treatment

Patrick A. Torres, John A. Helmstetter, Adam M. Kaye and Alan David Kaye
Ochsner Journal March 2015, 15 (1) 58-69;

REFERENCES

  1. ↵
    1. Huerta-Alardín AL,
    2. Varon J,
    3. Marik PE
    (4, 2005) Bench-to-bedside review: Rhabdomyolysis––an overview for clinicians. Crit Care 9(2):158–169, pmid:15774072.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Cervellin G,
    2. Comelli I,
    3. Lippi G
    (6, 2010) Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 48(6):749–756, pmid:20298139.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Bosch X,
    2. Poch E,
    3. Grau JM
    (7 2, 2009) Rhabdomyolysis and acute kidney injury. N Engl J Med 361(1):62–72, pmid:19571284.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Book of Numbers 11:18–34.
  5. ↵
    1. Korkmaz I
    (11, 2011) Kukul Güven FM, Eren SH, Dogan Z. Quail consumption can be harmful. J Emerg Med 41(5):499–502, pmid:18963719.
    OpenUrlPubMed
  6. ↵
    1. Billis AG,
    2. Kastanakis S,
    3. Giamarellou H,
    4. Daikos GK
    (9 25, 1971) Acute renal failure after a meal of quail. Lancet 2(7726):702, pmid:4105725.
    OpenUrlPubMed
  7. ↵
    1. Lewis DC,
    2. Metallinos-Katzaras E,
    3. Grivetti LE
    (1987) Coturnism: human poisoning by European migratory quail. J Cultur Geogr 7(2):51–65.
    OpenUrl
  8. ↵
    1. Rizzi D,
    2. Basile C,
    3. Di Maggio A,
    4. et al.
    (1991) Clinical spectrum of accidental hemlock poisoning: neurologic manifestations, rhabdomyolysis and acute tubular necrosis. Nephrol Dial Transplant 6(12):939–943, pmid:1798593.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Bagley WH,
    2. Yang H,
    3. Shah KH
    (10, 2007) Rhabdomyolysis. Intern Emerg Med 2(3):210–218, pmid:17909702.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Vanholder R,
    2. Sever MS,
    3. Erek E,
    4. Lameire N
    (8, 2000) Rhabdomyolysis. J Am Soc Nephrol 11(8):1553–1561, pmid:10906171.
    OpenUrlFREE Full Text
  11. ↵
    1. Bywaters EG,
    2. Beall D
    (3 22, 1941) Crush injuries with impairment of renal function. Br Med J 1(4185):427–432, pmid:20783577.
    OpenUrlFREE Full Text
  12. ↵
    1. Pasternak RC,
    2. Smith SC Jr.,
    3. Bairey-Merz CN,
    4. et al.
    (9, 2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 33(9):2337–2341, pmid:12215610.
    OpenUrlFREE Full Text
  13. ↵
    1. Kasaoka S,
    2. Todani M,
    3. Kaneko T,
    4. et al.
    (12, 2010) Peak value of blood myoglobin predicts acute renal failure induced by rhabdomyolysis. J Crit Care 25(4):601–604, pmid:20537502.
    OpenUrlPubMed
  14. ↵
    1. Watanabe T
    (12, 2001) Rhabdomyolysis and acute renal failure in children. Pediatr Nephrol 16(12):1072–1075, pmid:11793103.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Watemberg N,
    2. Leshner RL,
    3. Armstrong BA,
    4. Lerman-Sagie T
    (4, 2000) Acute pediatric rhabdomyolysis. J Child Neurol 15(4):222–227, pmid:10805187.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Al-Ismaili Z,
    2. Piccioni M,
    3. Zappitelli M
    (10, 2011) Rhabdomyolysis: pathogenesis of renal injury and management. Pediatr Nephrol 26(10):1781–1788, pmid:21249398.
    OpenUrlPubMed
  17. ↵
    1. Khan FY
    (10, 2009) Rhabdomyolysis: a review of the literature. Neth J Med 67(9):272–283, pmid:19841484.
    OpenUrlPubMedWeb of Science
  18. ↵
    1. Melli G,
    2. Chaudhry V,
    3. Cornblath DR
    (11, 2005) Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 84(6):377–385, pmid:16267412.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Mannix R,
    2. Tan ML,
    3. Wright R,
    4. Baskin M
    (11, 2006) Acute pediatric rhabdomyolysis: causes and rates of renal failure. Pediatrics 118(5):2119–2125, pmid:17079586.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Jukema JW,
    2. Cannon CP,
    3. de Craen AJ,
    4. Westendorp RG,
    5. Trompet S
    (9 4, 2012) The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60(10):875–881, pmid:22902202.
    OpenUrlFREE Full Text
  21. ↵
    1. U.S. Food and Drug Administration
    FDA announces safety changes in labeling for some cholesterol-lowering drugs. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm293623.htm. February 28, 2012. Updated March 2, 2012. Accessed November 21, 2014.
  22. ↵
    1. Chatzizisis YS,
    2. Koskinas KC,
    3. Misirli G,
    4. Vaklavas C,
    5. Hatzitolios A,
    6. Giannoglou GD
    (3 1, 2010) Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33(3):171–187, pmid:20158283.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Joy TR,
    2. Hegele RA
    (6 16, 2009) Narrative review: statin-related myopathy. Ann Intern Med 150(12):858–868, pmid:19528564.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Bays H
    (4 17, 2006) Statin safety: an overview and assessment of the data––2005. Am J Cardiol 97((8A)):6C–26C.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Antons KA,
    2. Williams CD,
    3. Baker SK,
    4. Phillips PS
    (5, 2006) Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119(5):400–409, pmid:16651050.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Fernandez G,
    2. Spatz ES,
    3. Jablecki C,
    4. Phillips PS
    (6, 2011) Stain myopathy: a common dilemma not reflected in the clinical trials. Cleve Clin J Med 78(6):393–403, pmid:21632911.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Guyton JR
    (4 17, 2006) Benefit versus risk in statin treatment. Am J Cardiol 97((8A)):95C–97C.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Thompson PD,
    2. Clarkson P,
    3. Karas RH
    (4 2, 2003) Statin-associated myopathy. JAMA 289(13):1681–1690, pmid:12672737.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Davidson MH,
    2. Clark JA,
    3. Glass LM,
    4. Kanumalla A
    (4 17, 2006) Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 97((8A)):32C–43C.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Staffa JA,
    2. Chang J,
    3. Green L
    (2 14, 2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346(7):539–540, pmid:11844864.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Kashani A,
    2. Phillips CO,
    3. Foody JM,
    4. et al.
    (12 19, 2006) Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114(25):2788–2797, pmid:17159064.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Allison RC,
    2. Bedsole DL
    (8, 2003) The other medical causes of rhabdomyolysis. Am J Med Sci 326(2):79–88, pmid:12920439.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Tomaszewski M,
    2. Stępień KM,
    3. Tomaszewska J,
    4. Czuczwar SJ
    (2011) Statin-induced myopathies. Pharmacol Rep 63(4):859–866, pmid:22001973.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Rowan CG,
    2. Brunelli SM,
    3. Munson J,
    4. et al.
    (5, 2012) Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in the Health Improvement Network. Pharmacoepidemiol Drug Saf 21(5):494–506, pmid:22422642.
    OpenUrlPubMed
  35. ↵
    1. Jacobson TA
    (11 1, 2004) Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 94(9):1140–1146, pmid:15518608.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Law M,
    2. Rudnicka AR
    (4 17, 2006) Statin safety: a systematic review. Am J Cardiol 97((8A)):52C–60C.
    OpenUrlPubMedWeb of Science
  37. ↵
    1. Goh IX,
    2. How CH,
    3. Tavintharan S
    (3, 2013) Cytochrome P450 drug interactions with statin therapy. Singapore Med J 54(3):131–135, pmid:23546024.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Jones PH,
    2. Davidson MH
    (1 1, 2005) Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95(1):120–122, pmid:15619408.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Pan WJ,
    2. Gustavson LE,
    3. Achari R,
    4. et al.
    (3, 2000) Lack of clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40(3):316–323, pmid:10709162.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Davidson MH
    (11 20, 2002) Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 90((10B)):50K–60K.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Landau ME,
    2. Kenney K,
    3. Deuster P,
    4. Campbell W
    (3, 2012) Exertional rhabdomyolysis: a clinical review with a focus on genetic influences. J Clin Neuromuscul Dis 13(3):122–136, pmid:22538307.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Schwaber MJ,
    2. Liss HP,
    3. Steiner I,
    4. Brezis M
    (3 1, 1994) Hazard of sauna use after strenuous exercise. Ann Intern Med 120(5):441–442, pmid:8304671.
    OpenUrlPubMed
  43. ↵
    1. Alpers JP,
    2. Jones LK Jr.
    (10, 2010) Natural history of exertional rhabdomyolysis: a population-based analysis. Muscle Nerve 42(4):487–491, pmid:20730874.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Warren JD,
    2. Blumbergs PC,
    3. Thompson PD
    (3, 2002) Rhabdomyolysis: a review. Muscle Nerve 25(3):332–347, pmid:11870710.
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Loke J,
    2. MacLennan DH
    (5, 1998) Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med 104(5):470–486, pmid:9626031.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Bagnulo H,
    2. Rodríguez F
    (2, 2001) Rhabdomyolysis during a case of streptococcal toxic shock syndrome [in Spanish]. Enferm Infecc Microbiol Clin 19(2):82–83, pmid:11333578.
    OpenUrlPubMed
  47. ↵
    1. Erdogan H,
    2. Yilmaz A,
    3. Kal O,
    4. Erdogan A,
    5. Arslan H
    (2006) Rhabdomyolysis-induced acute renal failure associated with legionnaires' disease. Scand J Urol Nephrol 40(4):345–346, pmid:16916778.
    OpenUrlPubMed
  48. ↵
    1. Swaringen JC,
    2. Seiler JG 3rd.,
    3. Bruce RW Jr.
    (6, 2000) Influenza A induced rhabdomyolysis resulting in extensive compartment syndrome. Clin Orthop Relat Res (375):243–249, pmid:10853175.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Paletta CE,
    2. Lynch R,
    3. Knutsen AP
    (3, 1993) Rhabdomyolysis and lower extremity compartment syndrome due to influenza B virus. Ann Plast Surg 30(3):272–273, pmid:8494311.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Peraldi MN,
    2. Maslo C,
    3. Akposso K,
    4. Mougenot B,
    5. Rondeau E,
    6. Sraer JD
    (6, 1999) Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol Dial Transplant 14(6):1578–1585, pmid:10383033.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Wang YM,
    2. Zhang Y,
    3. Ye ZB
    (2006) Rhabdomyolysis following recent severe coxsackie virus infection in patient with chronic renal failure: one case report and a review of the literature. Renal Fail 28(1):89–93.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Osamah H,
    2. Finkelstein R,
    3. Brook JG
    (Mar-Apr 1995) Rhabdomyolysis complicating acute Epstein-Barr virus infection. Infection 23(2):119–120, pmid:7622260.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Wong WM
    (8, 2004) Wai-Hung Shek T, Chan KH, Chau E, Lai KC. Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy. J Gastroenterol Hepatol 19(8):952–953, pmid:15242511.
    OpenUrlPubMed
  54. ↵
    1. Shanmugam S,
    2. Seetharaman M
    (12, 2008) Viral rhabdomyolysis. South Med J 101(12):1271–1272, pmid:19005459.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Will MJ,
    2. Hecker RB,
    3. Wathen PI
    (9, 1996) Primary varicella-zoster-induced rhabdomyolysis. South Med J 89(9):915–920, pmid:8790319.
    OpenUrlPubMedWeb of Science
  56. ↵
    1. Gupta M,
    2. Ghaffari M,
    3. Freire AX
    (4, 2008) Rhabdomyolysis in a patient with West Nile encephalitis and flaccid paralysis. Tenn Med 101(4):45–47, pmid:18488686, Erratum in: Tenn Med. 2008 Jun;101(6):61.
    OpenUrlPubMed
  57. ↵
    1. Gabow PA,
    2. Kaehny WD,
    3. Kelleher SP
    (5, 1982) The spectrum of rhabdomyolysis. Medicine (Baltimore) 61(3):141–152, pmid:7078398.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Better OS,
    2. Abassi ZA
    (5 17, 2011) Early fluid resuscitation in patients with rhabdomyolysis. Nat Rev Nephrol 7(7):416–422, pmid:21587227.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Elsayed EF,
    2. Reilly RF
    (1, 2010) Rhabdomyolysis: a review, with emphasis on the pediatric population. Pediatr Nephrol 25(1):7–18, pmid:19529963.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Fleisher LA
    1. Cereda M,
    2. Horak J,
    3. Neligan PJ
    (2006) in Anesthesia and Uncommon Diseases. 5th ed, Renal diseases, ed Fleisher LA (Saunders Elsevier; Philadelphia, PA) In, ed, pp 229–260.
  61. ↵
    1. Muenster T,
    2. Mueller C,
    3. Forst J,
    4. Huber H,
    5. Schmitt HJ
    (10, 2012) Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: a review of 232 cases. Eur J Anaesthesiol 29(10):489–494, pmid:22801582.
    OpenUrlPubMed
  62. ↵
    1. Segura LG,
    2. Lorenz JD,
    3. Weingarten TN,
    4. et al.
    (9, 2013) Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Paediatr Anaesth 23(9):855–864, pmid:23919455.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Coco TJ,
    2. Klasner AE
    (4, 2004) Drug-induced rhabdomyolysis. Curr Opin Pediatr 16(2):206–210, pmid:15021204.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Weiner AL,
    2. Vieira L,
    3. McKay CA,
    4. Bayer MJ
    (5, 2000) Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18(4):447–451, pmid:10802423.
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    1. Gurnaney H,
    2. Brown A,
    3. Litman RS
    (10, 2009) Malignant hyperthermia and muscular dystrophies. Anesth Analg 109(4):1043–1048, pmid:19762730.
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    1. Friedman S,
    2. Baker T,
    3. Gatti M,
    4. Simon G,
    5. Paskin S
    (8, 1995) Probable succinylcholine-induced rhabdomyolysis in a male athlete. Anesth Analg 81(2):422–423, pmid:7618742.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Ryan JF,
    2. Kagen LJ,
    3. Hyman AI
    (10 7, 1971) Myoglobinemia after a single dose of succinylcholine. N Engl J Med 285(15):824–827, pmid:4998942.
    OpenUrlPubMed
  68. ↵
    1. Wong JM
    (Sep-Oct 2010) Propofol infusion syndrome. Am J Ther 17(5):487–491, pmid:20844346.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Stelow EB,
    2. Johari VP,
    3. Smith SA,
    4. Crosson JT,
    5. Apple FS
    (4, 2000) Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem 46(4):577–581, pmid:10759487.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Mehta N,
    2. DeMunter C,
    3. Habibi P,
    4. Nadel S,
    5. Britto J
    (9 4, 1999) Short-term propofol infusions in children. Lancet 354(9181):866–867, pmid:10485752.
    OpenUrlPubMedWeb of Science
  71. ↵
    1. Burrow BK,
    2. Johnson ME,
    3. Packer DL
    (7, 2004) Metabolic acidosis associated with propofol in the absence of other causative factors. Anesthesiology 101(1):239–241, pmid:15220796.
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Roberts RJ,
    2. Barletta JF,
    3. Fong JJ,
    4. et al.
    (2009) Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 13(5):R169, pmid:19874582.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords